719 results on '"Hideshima, T"'
Search Results
52. INHIBITION OF THE STK4 KINASE RESTORES THE HIPPO CO-FACTOR YAP1 AND INDUCES DNA-DAMAGE MEDIATED APOPTOSIS IN MULTIPLE MYELOMA CELLS
53. Serine/Threonine Kinase STK4 Is a Novel Target in Myeloma
54. Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
55. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
56. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
57. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma
58. The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma
59. The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma
60. CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation
61. TARGETING ANGIOGENESIS VIA A C-MYC/HIF-1 alpha-DEPENDENT PATHWAY IN MM
62. Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis
63. Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling
64. Upregulation of c-Jun induces cell death via caspase- triggered c-Abl cleavage in human multiple myeloma
65. Targeting PKC informs in MM by enzastaurin (LY317615.HCL)
66. C-jun and C-ABL in human multiple myeloma cell death
67. Targeting proteinkinase C alters ER-stress and b-catenin signaling in multiple myeloma: Therapeutic implications
68. The small-molecule VEGF-receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
69. Occupied and unoccupied electronic structures of an L-cysteine film studied by core-absorption and resonant photoelectron spectroscopies
70. Up-regulation of c-Jun contributes to induction of apoptosis by Adaphostin in human multiple myeloma cells
71. Targeting the Ubiquitin-proteasome System in Multiple Myeloma: Examining the Roots of Success
72. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
73. A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma
74. Fatty acid synthase is a novel therapeutic target in multiple myeloma
75. Molecular Motion in Solid State Polymers
76. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
77. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
78. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma
79. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
80. HMG-CoA inhibitors (statins) induce growth arrest, apoptosis of multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) cells and enhance their sensitivity to conventional or novel therapies. Molecular profiling of HMG-CoA inhibition in MM/WM and framework for translation to therapeutic application
81. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors
82. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
83. Pathological crystallization of human immunoglobulins
84. β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome–aggresome–autophagosome–lysosome pathway
85. Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma
86. The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM).
87. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells
88. MLN-8237
89. Effect of the specific P53 stabilizer CBS9106 on multiple myeloma (MM)
90. B281 Ciliary Proteins and Hedgehog Pathway in Multiple Myeloma
91. B026 CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation
92. A349 Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib
93. B483 A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma
94. B540 The Effect of Insulin-Like Growth Factor-1 in Waldenström Macroglobulinemia
95. B203 A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease
96. A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma
97. B569 Targeting the Sp1 Transcription Factor in Multiple Myeloma
98. B454 Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis
99. B469 Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma
100. B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.